Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Susanne Kielland"'
Autor:
Frantz Rom Poulsen, Mikkel Warming Pedersen, Susanne Kielland, Henning B. Boldt, Bjarne Winther Kristensen, Arnon Møldrup Knudsen, Rikke Hedegaard Dahlrot, Mia Dahl Sørensen, Ida Eilertsen, Sune Munthe
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-13 (2020)
Knudsen, A M, Eilertsen, I, Kielland, S, Pedersen, M W, Sørensen, M D, Dahlrot, R H, Boldt, H B, Munthe, S, Poulsen, F R & Kristensen, B W 2020, ' Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas ', Scientific Reports, vol. 10, 9285 . https://doi.org/10.1038/s41598-020-66236-x
Scientific Reports
Knudsen, A M, Eilertsen, I, Kielland, S, Pedersen, M W, Sørensen, M D, Dahlrot, R H, Boldt, H B, Munthe, S, Poulsen, F R & Kristensen, B W 2020, ' Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas ', Scientific Reports, vol. 10, 9285 . https://doi.org/10.1038/s41598-020-66236-x
Scientific Reports
Most glioblastoma patients have a dismal prognosis, although some survive several years. However, only few biomarkers are available to predict the disease course. EGR1 and EGR3 have been linked to glioblastoma stemness and tumour progression, and thi
Autor:
Arnon Møldrup Knudsen, C S Mellegaard, Sune Munthe, Rikke Hedegaard Dahlrot, Henning B. Boldt, Susanne Kielland, M W Pedersen, Ida Eilertsen, Bjarne Winther Kristensen, Frantz Rom Poulsen, Mia D. Sørensen
Publikováno v:
Neuro-Oncology. 20:iii284-iii284
BACKGROUND: Gliomas are the most frequent primary brain tumors. For the most malignant glioma - the glioblastoma - the median survival is only 15 months. Few prognostic biomarkers are useful in daily practice, and new markers are urgently needed. EGR
Autor:
Sune Munthe, Caspar S. Mellegaard, Henning B. Boldt, Arnon Møldrup Knudsen, Ida Eilertsen, Susanne Kielland, Bjarne Winther Kristensen
Publikováno v:
Cancer Research. 78:2649-2649
Introduction Gliomas are the most frequent primary brain tumors. For the most malignant glioma - the glioblastoma - the median survival is below 15 months. Since only few prognostic biomarkers are of benefit in daily practice, new markers are urgentl